Marlana Keeton, APRN
Family · Lexington, KYNPI 1023551504
Payments from drug & device makers
Across 618 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- GSK$2K
- AstraZeneca$1K
- Grifols USA, LLC$855
- Mylan Specialty L.p.$595
- Regeneron Healthcare Solutions, Inc.$538
- plus $5K from 31 others
What the payments were for
- Food & beverage$10,88697%
- Education$3603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 124 | $1,895 |
| GSK | 118 | $1,655 |
| AstraZeneca | 40 | $1,117 |
| Grifols USA, LLC | 43 | $855 |
| Mylan Specialty L.p. | 36 | $595 |
| Regeneron Healthcare Solutions, Inc. | 29 | $538 |
| Sanofi | 27 | $526 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $404 |
| Insmed, Inc. | 16 | $372 |
| Genentech USA, Inc. | 26 | $318 |
| Jazz Pharmaceuticals Inc. | 8 | $287 |
| Harmony Biosciences LLC | 11 | $265 |
| Amgen | 14 | $232 |
| Actelion Pharmaceuticals US, Inc. | 13 | $214 |
| United Therapeutics Corporation | 10 | $194 |
| Gilead | 10 | $185 |
| Pfizer | 10 | $182 |
| Axsome Therapeutics, Inc. | 7 | $175 |
| Johnson & Johnson | 7 | $171 |
| Mallinckrodt Hospital Products Inc. | 6 | $165 |
| Sanofi-aventis U.S. LLC | 2 | $163 |
| Electromed, Inc. | 10 | $120 |
| Viatris Specialty LLC | 4 | $76 |
| Inogen, Inc. | 3 | $72 |
| AbbVie | 3 | $69 |
| Paratek Pharmaceuticals, Inc. | 4 | $67 |
| Verona Pharma, Inc. | 2 | $63 |
| Pulmonx Corporation | 2 | $47 |
| Baxter Healthcare | 2 | $43 |
| Inspire Medical Systems, Inc. | 2 | $38 |
| CSL Behring | 1 | $33 |
| Mayne Pharma Commercial LLC | 1 | $28 |
| Tactile Systems Technology Inc | 1 | $20 |
| Bio Products Laboratory USA, Inc. | 1 | $19 |
| Bayer | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,246 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $287,990 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 262 | $276,262 |
| Dupixent PenDupilumab | 64 | $259,318 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $162,357 |
| Dupixent SyringeDupilumab | 29 | $131,031 |
| Bosentan | 13 | $129,285 |
| Spiriva RespimatTiotropium Bromide | 114 | $100,984 |
| NucalaMepolizumab | 25 | $91,992 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 90 | $77,251 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 74 | $53,302 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $50,684 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $36,510 |
| SymbicortBudesonide/Formoterol Fumarate | 90 | $34,694 |
| Pirfenidone | 17 | $23,921 |
| Advair HfaFluticasone Propion/Salmeterol | 41 | $21,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,655 | $481,661485 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,895 | $460,276239 claims |
| Grifols USA, LLCProlastin C | $855 | $162,35714 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $214 | $129,28513 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,117 | $111,945180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Lexington
- Elizabeth SaltLexington$89K
- Alisha ClemonsLexington$55K
- Timothy SmallwoodLexington$27K
- Lauren MaupinLexington$18K
- Angela CrutcherLexington$16K
- Emily MesserliLexington$13K
- Rhiannon BlackLexington$12K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.